<DOC>
	<DOCNO>NCT01060111</DOCNO>
	<brief_summary>The purpose study investigate adequacy ( reasonably good ) topiramate therapy ( medicine medical care give participant disease condition ) prevention migraine ( type severe headache occur periodically often associate nausea , vomit , constipation diarrhea ) compare standard titration ( slow increase drug dosage , guide patient 's response ) therapy slow titration therapy slow titration therapy boost concurrent use propranolol participant migraine without aura ( ear ) equal 2 attack per month .</brief_summary>
	<brief_title>An Efficacy Tolerability Study Topiramate Participants With Migraine</brief_title>
	<detailed_description>This prospective ( study follow participant forward time ) , single-blind ( Physician know intervention ) , randomize ( study drug assign chance ) comparative multi-center ( conduct 1 center ) study assess appropriate administration method topiramate preventive therapy participant migraine . The study consist 3 period : Screening period ( 4 week ) , Treatment period consist 2 titration period ( 3 week ) Maintenance period ( 4 week ) . During Screening period , diagnosis participant ' headache , symptom severity migraine investigate headache diary participant select treatment period . In treatment period , select participant randomly assign either 3 topiramate therapy : 'topiramate standard group ' , 'topiramate slow group ' , 'topiramate slow plus propranolol ( booster ) group ' . In 'topiramate standard group ' - participant receive initial dose topiramate 25 milligram ( mg ) daily dose topiramate increase 25 mg per day interval 1-week target dose 50 mg 100 mg Week 6 ; maintenance dose 50 mg 100 mg administer twice daily Week 10 per Physician 's discretion . In 'topiramate slow group ' - participant start initial dose 25 mg daily dose increase 25 mg per day interval 2-weeks dose 50 mg 100 mg Week 6 . A maintenance dose 50 mg 100 mg administer twice daily Week 10 per Physician 's discretion . In 'topiramate slow plus propranolol ( booster ) group ' - participant follow dosage regimen 'topiramate slow group ' along concurrent administration booster dose propranolol 80 mg daily ( 40 mg time morning evening ) 6 week . The participant primarily evaluate reduction migraine frequency Week 7 10 use headache diary questionnaire maintain . Participants ' quality life assess use Migraine Disability Assessment ( MIDAS ) score intensity pain migraine assess use Visual Analogue Scale ( VAS ) . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<criteria>Particpants sign consent form Participants 3 14 episode migraine month Participants whose duration migraine least 6 month Participants read understand migraine disability assessment ( MIDAS ) questionnaire Female Participants use appropriate contraception method negative pregnancy test result Participants whose headache attack Baseline study period assume caused drug withdrawal syndrome Participants whose migraine appear first 50 year age Participants take anticonvulsant ( valproic acid , gabapentin ) , beta adrenergic blocker ( propranolol ) calcium antagonist ( sibelium , verapamil , diltiazem ) topiramate propranolol within last 8 week Participants progressive neurological ( pertain nervous system ) disorder Participants severe renal ( pertain kidney ) disorder , hepatic ( pertain liver ) failure diabetes ( disorder decrease insulin body body 's insulin effective , result high blood sugar , increase thirst urine , many side effect ) history renal calculus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Migraine</keyword>
	<keyword>Topiramate</keyword>
	<keyword>Propranolol</keyword>
</DOC>